Refining a preclinical model of viral myocarditis in accordance with biotech standards Authors: Jonas Stewen, Julia Riedesel, Juliane Stein, Brandon H Greene, Svenja Rohde, Sonja Suess, Bjoern Keiner, Priya Panjwani, Padmapriya Ponnuswamy, Juan E Camacho Londoño Published: 2026 ABSTRACT AbstractBackgroundViral myocarditis is a clinically relevant inflammatory heart disease that can progress to dilated cardiomyopathy and heart failure. However, preclinical models often suffer from limited translational relevance and high animal burden.MethodsThis study aimed to refine a murine model of Coxsackievirus B3 (CVB3)‐induced myocarditis by integrating dietary and imaging innovations to improve animal welfare, data quality, and clinical applicability. BALB/cJ mice were infected with heart‐passaged CVB3 and monitored for up to 56 days. A hydrolyzed amino acid diet was introduced to mitigate CVB3‐induced pancreatitis and associated weight loss. Cardiac function was assessed using 1D, 2D, and 4D echocardiography, including speckle‐tracking strain analysis.ResultsThe refined diet significantly reduced animal health burden, reduced weight loss, and stabilized blood glucose, during development of cardiac inflammation and fibrosis. 4D echocardiography provided a highly sensitive and reproducible detection of systolic dysfunction, while strain analysis revealed early and regional myocardial impairment, closely mirroring clinical myocarditis phenotypes. Histopathological and AI‐based analyses confirmed dose‐ and time‐dependent inflammation and fibrosis, with peak inflammation at day 7 and persistent abnormalities through day 56.ConclusionsIn summary, this model offers a robust and ethically optimized platform for translational research and therapeutic development in inflammatory cardiomyopathies, aligned with the principles of the 3Rs.Keywords: 3Rs, animal welfare, coxsackie, mouse, translation INTRODUCTION The global burden of viral infections on human health and society has been drastically illustrated by the COVID‐19 pandemic, emphasizing the urgent need for intensified research into viral pathogenesis and the pivotal role of biomedical science in advancing diagnostic and therapeutic strategies. 1 , 2 , 3 Viral myocarditis is a clinically significant inflammatory condition of the myocardium, characterized by immune cell infiltration and varying degrees of cardiomyocyte injury, which can progress to dilated cardiomyopathy (DCM) and chronic heart failure. 4 , 5 It most commonly presents in young adults under the age of 40, with an estimated global prevalence ranging from 10.2 to 105.6 cases per 100 000 population and approximately 1.8 million cases reported annually. 6 , 7 , 8 , 9 Reflecting its clinical importance, the 2025 ESC Guidelines on Inflammatory Myocardial and Pericardial Syndromes published a comprehensive framework for the diagnosis and management of myocarditis, emphasizing refined imaging strategies as well as personalized therapeutics. 10 In clinical and preclinical settings, Coxsackievirus B3 (CVB3) is one of the most frequently studied viral pathogens that cause myocarditis. Since the 1970s, murine models of CVB3‐induced myocarditis have been crucial in elucidating disease mechanisms and evaluating potential therapies. 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 However, as the field advances, increasing emphasis is being placed on refining these models in accordance with the principles of the 3Rs (Replacement, Reduction, and Refinement) to enhance reproducibility, translational relevance, and compliance with animal welfare standards. 23 , 24 , 25 Traditionally, the functional evaluation of myocarditis models has predominantly used conventional one‐ (1D) or two‐dimensional (2D) echocardiography, which estimates global systolic function through parameters such as left ventricular ejection fraction (LVEF) and fractional shortening (FS). 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 Although widely used, these imaging modalities rely on geometric assumptions that may not accurately represent the true anatomy of the heart, especially under pathological conditions. In contrast, four‐dimensional (4D) echocardiography represents an advanced method for volumetric cardiac assessment. 34 , 35 , 36 , 37 , 38 , 39 Considering the real‐time, three‐dimensional geometry of the left ventricle, 4D imaging provides more accurate and reproducible measurements. This increased precision offers the potential to reduce overall animal usage, aligning with the goal of reducing animal use in preclinical research. Furthermore, recent advancements such as speckle‐tracking echocardiography and myocardial strain analysis have emerged as valuable tools in both clinical and preclinical cardiology. 20 , 35 , 39 , 40 , 41 , 42 , 43 , 44 These techniques offer enhanced sensitivity for detecting subtle or regional changes in myocardial function that precede overt alterations in LVEF. Their application in murine models enhances the translational relevance of functional readouts and improves monitoring of disease progression and/or therapeutic response. CVB3 myocarditis mouse models are complicated by severe systemic disease in addition to cardiac involvement, with the pancreas being particularly susceptible to viral injury. 45 , 46 , 47 , 48 , 49 CVB3‐induced pancreatitis results in significant weight loss, which can affect the interpretation of cardiac phenotypes. Although genetically engineered CVB3 variants have been developed to reduce pancreatic tropism, these fail to elicit cardiac dysfunction, thereby limiting their use in translational studies. 48 An alternative strategy is to mitigate pancreatic injury through supportive care measures that improve animal health while maintaining cardiac involvement. Here, we aimed to refine a BALB/cJ mouse model of CVB3‐induced myocarditis through several key improvements. To our knowledge, this is the first study to comprehensively analyze cardiac function spanning both early and late stages of infection, using 1D, 2D, and 4D imaging, as well as speckle‐tracking strain analysis. These approaches enabled identification of robust and low‐variability functional parameters, enhancing reproducibility and sensitivity. In parallel, we introduced a hydrolyzed amino acid diet that significantly mitigated weight loss due to CVB3‐induced pancreatitis, improving animal welfare without compromising cardiac pathology. Lastly, we provide practical guidance for biosafety level 2 (BSL2) compliance to facilitate broader adoption of this refined model. Together, these improvements optimize reproducibility, reduce animal burden, and enhance translational relevance of the CVB3 myocarditis mouse model. METHODS Animal experiments All animal experiments were approved and performed according to the regulations of the Regional Council of Giessen (V 54–19 c 20 15 h 01 Phl MR Nr. G 41/2023) and the internal animal welfare committee and also conform to the guidelines from Directive (2010)/63/EU of the European Parliament on the protection of animals used for scientific purposes and internal CSL policy. BALB/cJ mice (Strain #:000651) were bred at Charles River Breeding Laboratories, Germany, and later transferred to our facility where we performed in vivo studies under BSL2 conditions and according to local and internal regulations. Biosafety procedures, including details of a PCR‐based wipe test (Figure S1) that we validated for monitoring complete surface disinfection, are contained in Supplemental Information. After arrival, mice were maintained as described in internal standard operating procedures, including a 12‐h light–dark cycle in biocontainment cages (ISOcage N system, Tecniplast, Italy) and, when possible, in groups of 2–3 mice. Mice had an acclimation period of at least 1 week before any procedure. Water and standard food (M‐H 10 No. V1534‐703, ssniff, Germany) were available ad libitum. DietGel® Boost and DietGel® Recovery diets (ClearH2O, USA) were included as caloric/nutrient support to reduce the impact of procedures (e.g., virus infection, anesthesia, and temperature reduction by gel application after echocardiography). Additionally, a special diet designed for exocrine pancreas insufficiency (Product No. S8626‐E010; ssniff Spezieldiäten GmbH, Germany) was included (see Table S1 for detailed composition), except for animals from the 10‐day observation period study. These additional diets were offered to the mice during the acclimatization period. Room temperature was maintained at 20–24°C and relative humidity at 40%–60%, in rooms with a complete air exchange rate of 20 times per hour. Enrichment included tunnels, nest materials, and aspen bricks (Plexx, Netherlands) provided as required. Animals were monitored daily, and all observations, including body weight and temperature, were documented. In addition, a standardized composite health score was assessed for each animal. Detailed scoring criteria (body condition, body weight change, behavior, general appearance, and grimace scale, among others) are provided in the Supplementary Methods. For animal identification and temperature monitoring, transponders (IPT‐300, Plexx) were subcutaneously implanted (left shoulder) under light isoflurane anesthesia at the end of the first echocardiography session. To induce viral myocarditis, 50 on day 0, male BALB/cJ mice aged 8–11 weeks were randomly assigned to groups and intraperitoneally (i.p.) injected with a total volume of 200 μL of either heart‐passaged CVB3 (Nancy strain, ATCC VR‐30), heart homogenate control, or MEM‐2 (Minimum Essential Medium containing 2% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin) as vehicle. Viral dosing was achieved by dilution of the heart passaged CVB3 stock to a final volume of 200 μL, resulting in the following groups: 2× dose (200 μL stock; 176 ± 42 plaque‐forming units [PFU]), 1× dose (100 μL stock +100 μL MEM‐2; 88 ± 21 PFU), 0.5× dose (50 μL stock +150 μL MEM‐2; 44 ± 10.5 PFU), and 0.1× dose (10 μL stock +190 μL MEM‐2; 8.8 ± 2.1 PFU). Echocardiography Echocardiography was performed following standardized protocols as outlined in recent publications on preclinical imaging 38 , 39 and adapted as described in an upcoming publication 51 . Mice were anesthetized with 1%–2.5% isoflurane in 100% oxygen, and imaging was performed using a Vevo F2 system (Fujifilm VisualSonics) equipped with a UHF57× linear array transducer (25–57 MHz). Cardiac parameters were quantified using VevoLab software (v5.10.0) by personnel blinded to treatment groups. At the end of the first and final imaging sessions, non‐fasting blood glucose levels were measured. A small blood sample was obtained via tail vein puncture using a 30G needle and analyzed with the Accu‐Tell® Blood Glucose Monitoring System using the dog modus (Accubiotech). Following the final echocardiography session, organs were isolated as previously described. 52 Briefly, animals were anesthetized with ketamine/xylazine (120 mg/kg and 16 mg/kg body weight, i.p.), sacrificed by cervical dislocation, and organs were harvested for subsequent analysis of allometric parameters and histological processing. Histology Mouse hearts were cut longitudinally and fixed in 10% formalin at a volume ≥ 20× the sample volume for 24 h at room temperature. Following fixation, samples were transferred to 0.2% formalin in phosphate buffered saline and stored at room temperature until further processing. After paraffin embedding using an automatic tissue processor (Leica TP1020), samples were sectioned at 5 μm thickness at various depths using a microtome (Leica RM2255). Sections were stained with hematoxylin and eosin (H&E) and Picro‐Sirius Red (PSR) to determine inflammation and fibrosis, respectively. Staining was performed using an autostainer (Leica ST5010) in combination with an automated glass coverslipper (Leica CV5030). Brightfield images were acquired using the Zeiss AxioScan Z1 microscope. Histopathologic scoring of inflammation and fibrosis was conducted by a pathologist (StageBio) blinded to treatment and timepoint of analysis of the animals. Inflammation was scored as follows: 1 indicated minimal changes affecting 1%–5% of the tissue, 2 indicated slight lesions (6%–20%), 3 indicated moderate lesions (21%–45%), 4 indicated marked lesions (46%–75%) and 5 indicated severe lesions (>75%). Fibrosis was scored using the same percentage‐based scale as inflammation indicating an increase in collagen areas within the myocardium. In addition, an artificial intelligence (AI) based quantitation (StageBio) was performed using Visiopharm software (Stewen et al., in preparation). Scoring and quantitation were performed for each animal using 3 sections per stain, collected at different tissue depths. Statistical analysis Echocardiography biomarkers such as ejection fraction and fraction shortening restricted to the closed interval [0, 100%] were analyzed using Beta distributed generalized linear mixed models (GLMM) with a logit link function. Regression models were fitted using restricted maximum likelihood (REML) for all outcomes with combined data from all groups and timepoints. Detailed statistical and power analysis are included in the Supplemental Information. RESULTS Heart‐passaged CVB3 induces systemic and cardiac manifestations of viral myocarditis Inoculation of mice with heart‐passaged CVB3, containing both viral particles and cardiac proteins, is known to induce acute myocarditis that can progress, in susceptible mouse lines, to chronic heart failure and DCM. 15 , 16 , 53 To assess the virulence of our heart‐passaged CVB3 stock and to confirm disease induction, as recommended by Prof. DeLisa Fairweather (personal communication), mice were injected with either 0.1× or 1× viral doses (8.8 ± 2.1 PFU and 88 ± 21 PFU, respectively), vehicle (MEM‐2 media), or a heart homogenate control, and evaluated 9–10 days post‐injection (Figure 1A,B). Body temperature remained stable across all groups throughout the study (Figure 1C). Virus (1×)‐treated animals exhibited progressive weight loss beginning 3 days post‐injection, reaching a maximum of 17% weight loss compared to baseline by day 10. The average weight loss was approximately 10% relative to baseline, despite including boost and recovery diet gels as supportive care (Figure 1D). No weight loss was observed in the (0.1×)‐treated group. The decline in body weight of the (1×)‐treated group correlated with significantly reduced blood glucose levels at day 9, indicating possible exocrine pancreas dysfunction, caused by CVB3‐induced pancreatitis (Figure 1E). 45 , 46 , 47 , 48 , 49 Blood glucose levels remained unchanged in all other groups. Allometric parameters and organ water contents are summarized in Table 1, with no overt differences observed between groups. Experimental design and pilot study characterizing the activity of heart‐passaged CVB3. (A) Scheme outlining experimental workflow. (B) Timeline of pilot study indicating treatment and assessment timepoints. (C) Plot of body temperature change relative to day 0, showing no significant differences across all groups. (D) Quantitation of body weight change compared to day 0. Virus (1×)‐treated mice show progressive reduction in body weight. (E) Decreased blood glucose levels in virus (1×)‐treated animals. Graph shows non‐fasting blood glucose levels at day −7 (basal) and day 9 (final). (F) Validation of inflammation upon virus injection. Graphs show histopathologic scores of inflammation derived from H&E and MT staining, and quantitation of inflamed tissue area using VisioPharm's AI‐based analysis. Virus (1×)‐treated animals show highest degree of inflammation. (G, H) Analysis of systolic heart function, showing LVEF derived from 4D‐imaging (G) and endocardial longitudinal strain analysis (H). Groups included vehicle, heart homogenate, virus 0.1× (8.8 ± 2.1 PFU), and virus 1× (88 ± 21 PFU) (n = 4–5 per group). Data are presented as mean ± SD. Statistical significance is indicated as *p < 0.05, **p < 0.01, and ***p < 0.001, based on comparisons against the vehicle group at the final timepoint. AI, artificial intelligence; H&E, hematoxylin and eosin staining; LVEF, left ventricular ejection fraction; MT, Masson's trichrome staining; SD, standard deviation. TABLE 1Allometric parameters of the pilot study.ParameterVehicleHeart homogenateVirus 0.1×Virus 1×Bodyweight, g24.68 ± 3.3526.38 ± 1.0227.70 ± 4.2923.62 ± 2.78Heart weight, mg135.25 ± 25.84119.50 ± 2.65115.50 ± 15.86111.60 ± 9.02Lung weight, mg175.33 ± 13.65196.75 ± 10.18175.25 ± 15.71175.80 ± 39.31Liver weight, mg1198.67 ± 65.261186.50 ± 87.321264.75 ± 239.471038.75 ± 220.92Spleen weight, mg101.75 ± 14.8997.00 ± 18.6084.50 ± 10.6680.20 ± 3.03Kidney (right) weight, mg184.50 ± 28.64200.00 ± 9.42195.75 ± 46.94159.20 ± 17.05Kidney (left) weight, mg195.00 ± 22.57209.00 ± 10.55201.25 ± 42.74161.40 ± 22.42Tibia length, mm17.18 ± 0.1517.13 ± 0.4317.05 ± 0.1317.04 ± 0.13Heart weight/body weight, mg/g5.68 ± 2.054.53 ± 0.144.21 ± 0.534.74 ± 0.27Heart weight/tibia length, mg/mm7.88 ± 1.536.98 ± 0.296.77 ± 0.916.55 ± 0.49Lung weight/body weight, mg/g10.74 ± 8.157.48 ± 0.636.41 ± 0.847.39 ± 0.87Lung weight/tibia length, mg/mm14.33 ± 8.2911.48 ± 0.3410.28 ± 0.9510.31 ± 2.25Liver weight/bodyweight, mg/g35.75 ± 20.3145.06 ± 4.0845.49 ± 2.9635.88 ± 15.29Liver weight/tibia length, mg/mm53.94 ± 31.6869.26 ± 4.3074.16 ± 13.8950.97 ± 24.45Spleen weight/bodyweight, mg/g4.22 ± 1.043.70 ± 0.823.10 ± 0.533.42 ± 0.30Spleen weight/tibia length, mg/mm5.93 ± 0.885.65 ± 0.984.96 ± 0.654.71 ± 0.17Kidney weight/body weight, mg/g15.41 ± 0.8115.53 ± 0.9414.26 ± 1.4413.57 ± 0.30Kidney weight/tibia length, mg/mm22.09 ± 2.7223.89 ± 0.8623.27 ± 5.0318.81 ± 2.16Lung water content, %81.36 ± 0.7680.51 ± 1.3679.48 ± 2.7279.85 ± 1.97Liver water content, %68.32 ± 0.5367.18 ± 0.9666.86 ± 2.6167.58 ± 2.19Spleen water content, %81.15 ± 2.4278.69 ± 3.3877.62 ± 2.4878.32 ± 2.19Age at day of infection, weeks11.14 ± 0.0011.14 ± 0.0011.00 ± 0.1411.14 ± 0.00 Note: Group‐wise values for each allometric parameter, including mean ± standard deviation at day 10. Allometric parameters of the pilot study. Note: Group‐wise values for each allometric parameter, including mean ± standard deviation at day 10. Cardiac inflammation was assessed on day 10 by histopathological analysis of formalin‐fixed heart sections stained for H&E and Masson's trichrome (MT) (Figure 1F). Pathologist scoring revealed no inflammation in vehicle‐treated animals, while virus (1×)‐treated mice exhibited the highest inflammation scores, characterized by multifocal immune cell infiltration with distinct monocytes and macrophages, followed by the (0.1×)‐treated and heart homogenate groups. These findings were corroborated using AI‐based quantification of inflamed tissue area which also showed the highest percent of inflamed tissue in the virus (1×)‐treated group (Figure 1F). Additionally, signs of fibroplasia were observed in both virus‐treated groups (Figure S2A). Fibrosis was evaluated using PSR staining. While vehicle and heart homogenate groups showed no fibrosis, both virus‐treated groups showed mild fibrotic changes, with the virus (1×)‐treated group consistently scoring 1 across all animals (Figure S2B). However, AI‐based quantification of PSR‐positive tissue and fibrotic area did not replicate these findings (Figure S2C). This highlights the limitations of automated image analysis in detecting early fibrotic changes in this disease model. To assess changes in cardiac function, echocardiography was performed 1 week prior to injection and again on day 9 post‐injection (Figure 1B). A full list of echocardiographic parameters is provided in Table S1. Conventional and 4D imaging modalities did not detect significant changes in systolic function, including LVEF and FS, in virus‐treated animals (Figure 1G and Table S1). However, analysis of endocardial global longitudinal strain (GLS), which is more sensitive to early changes in cardiac contractility, revealed a trend toward reduced strain in the virus (1×)‐treated group compared to baseline and vehicle control, although this trend did not reach statistical significance (Figure 1H). Diastolic function, assessed via mitral valve Doppler, as well as structural parameters such as anterior and posterior wall thickness, remained unchanged across all groups (Table S1). These data confirmed that our heart‐passaged CVB3 induced early systemic and cardiac manifestations of viral myocarditis, including weight loss, hypoglycemia, myocardial inflammation, and early signs of systolic dysfunction. Refined diet attenuates weight loss in CVB3‐infected mice After confirming disease induction following infection with our heart‐passaged CVB3 stock (Figure 1D–H), we further characterized the dose‐dependent effects of CVB3 and assessed long‐term disease progression. A follow‐up study was conducted using lower (0.5×; 44 ± 10.5 PFU) and higher (2×; 176 ± 42 PFU) viral doses in addition to the previously tested 1× dose (88 ± 21 PFU) of the heart‐passaged CVB3 stock; these doses were in the range of the previously reported 102 PFU dose used in a comprehensive study evaluating time‐dependent disease progression until day 56. 54 Four independent cohorts were followed for 7, 14, 35, or 56 days post‐injection (Figure 2A). To improve animal welfare and to address the expected exocrine pancreatic insufficiency that may impair the breakdown of molecules like proteins and carbohydrates, we included a highly refined diet tailored to this condition. The formulation included purified amino acids among other easily absorbable nutrients and was introduced prior to virus injection. The full dietary composition is provided in Table S2. Diet refinement improves the weight loss burden of CVB3‐infected mice. (A) Scheme outlining timeline and assessment points of the characterization study. Four cohorts were monitored with different final timepoints (day 7, 14, 35, and 56). (B) Graphs showing body weight change of all cohorts over time. Purified amino acid diet led to attenuated body weight loss in virus treated animals. (C) Blood glucose analysis at baseline and final timepoints across all cohorts. Diet refinement improved blood glucose levels. Groups included vehicle, heart homogenate, and virus 0.5× (44 ± 10.5 PFU), 1× (88 ± 21 PFU), and 2× (176 ± 42 PFU) (n = 4–6 per group and timepoint). Data are presented as mean ± SD. d, day; SD, standard deviation. Compared to the previous study, the dietary refinement reduced both the magnitude and duration of body weight loss. All virus‐treated groups exhibited weight loss beginning 3 days post‐injection with animals from the (1×)‐treated and (2×)‐treated groups showing highest reductions. However, even the 2× virus dose resulted in only an average decrease of approximately 5% relative to baseline (Figure 2B and S3C). Importantly, weight loss was transient as animals began regaining weight by day 7 and, in the 56‐day cohort, approached vehicle group weights by day 21 (Figure 2B). Blood glucose levels showed no significant change across all timepoints and groups (Figure 2C). Consistent with these findings, animal health scoring revealed a reduced disease burden in mice receiving the hydrolyzed amino acid diet (Figure S3A,B). While virus (1×)‐treated animals on the standard diet exhibited a moderate health burden score, with maximum scores reaching up to 4 during the early phase of infection, animals receiving the same viral dose under the refined diet showed significantly lower average and peak health burden scores. Notably, animals challenged with a 2× viral dose under the amino acid diet also displayed a lower overall health burden compared to the 1× virus group on the standard diet, indicating a robust protective effect of the dietary intervention during early CVB3 infection. Histopathological analysis revealed dynamic changes in myocardial inflammation following CVB3 infection (Figure 3A–C). Inflammation peaked at day 7, particularly in virus (2×)‐treated animals, indicating a dose‐dependent effect at this early timepoint (Figure 3B). At days 7 and 14, multifocal mononuclear cell infiltration as well as minimal single cell necrosis of cardiomyocytes were observed. While inflammation declined at day 35, a significant increase was observed again on day 56 in all virus‐treated groups compared to vehicle (Figure 3A) with sparse foci of multifocal mononuclear cell infiltration and signs of fibroplasia. No significant difference was observed between vehicle and heart homogenate‐treated animals at any analysis timepoint. Fibrotic changes were mild across all timepoints and did not show a clear dose‐ or time‐dependent progression. A statistically significant increase in fibrosis was observed on day 7 in virus‐treated groups compared to vehicle controls. These changes reflect early reactive interstitial fibrosis rather than established fibrotic remodeling (Figure 3C). At later timepoints, fibrosis remained limited and was characterized by sparse interstitial collagen deposition, primarily localized to the tip of the interventricular septum and the left ventricular free wall (Figure 3C). Histopathological characterization of the CVB3‐induced myocarditis model. (A) Histopathologic scoring of inflammation (H&E) and fibrosis (PSR) across all cohorts. Inflammation severity correlated with viral dose and peaked at day 7. Fibrosis remained mild across groups and peaked at days 35 and 56. (B) Representative H&E‐stained heart sections from day 7, comparing vehicle and virus (2×)‐treated animals. Insets highlight inflammatory foci in virus‐treated animals. (C) Representative PSR‐stained heart sections from day 56, comparing vehicle and virus (2×)‐treated animals. Insets of virus‐treated animals show reactive interstitial fibrosis. (D) Confirmation of pathology findings using VisioPharm's AI‐based analysis. Graphs show total inflammation foci area, total nuclei count, and fibrotic area. Groups included vehicle, heart homogenate, virus 0.5× (44 ± 10.5 PFU), 1× (88 ± 21 PFU), and 2× (176 ± 42 PFU) (n = 4–6 per group and timepoint). Data are presented as mean ± SD or as boxplots showing the median, interquartile range, and whiskers extending to the minimum and maximum values. Statistical significance is indicated as *p < 0.05, **p < 0.01, and ***p < 0.001, based on comparisons against the vehicle group of each timepoint. AI, artificial intelligence; d, day; H&E, hematoxylin and eosin staining; PSR, Picro Sirius Red staining; SD, standard deviation. Inflammation was further quantified using an AI‐based approach, assessing total inflammatory foci area, total foci count, and total nuclei count (Figures 3D and S2D). These analyses confirmed the peak inflammatory response at day 7 and the dose‐dependent effect of viral load. Notably, peak inflammation coincided with increased spleen size in all virus‐treated groups, which normalized at later timepoints (Table 2). Likewise, fibrosis was quantified using an AI‐based approach assessing PSR‐positive area and fibrotic‐affected tissue area (Figures 3D and S2E). Corroborating the pathological scoring, fibrosis remained mild across all timepoints and groups but only showed a significant increase in the virus (2×)‐treated animals on day 56 post injection, indicating disease progression (Figure 3D). TABLE 2Allometric parameters of the characterization study.ParameterVehicleHeart homogenateVirus 0.5×Virus 1×Virus 2× Day 7 Bodyweight, g27.98 ± 1.0029.45 ± 0.0726.52 ± 1.0725.24 ± 2.4526.40 ± 1.69Heart weight, mg132.20 ± 9.42138.00 ± 5.66120.40 ± 6.58128.80 ± 15.93135.60 ± 7.57Lung weight, mg178.80 ± 20.90197.00 ± 55.15189.40 ± 12.01178.60 ± 16.46193.00 ± 21.04Liver weight, mg1215.60 ± 82.261197.00 ± 172.531161.80 ± 79.641242.40 ± 234.951294.80 ± 89.39Spleen weight, mg81.20 ± 9.3188.50 ± 26.16114.00 ± 12.02105.00 ± 23.09115.20 ± 3.42Kidney (R) weight, mg212.60 ± 10.36240.50 ± 30.41215.20 ± 10.99201.00 ± 24.92224.40 ± 15.63Kidney (L) weight, mg211.60 ± 16.95244.50 ± 30.41213.00 ± 7.18198.80 ± 24.74225.80 ± 19.23Tibia length, mm17.20 ± 0.1417.45 ± 0.6417.46 ± 0.3117.24 ± 0.4417.34 ± 0.19Heart weight/body weight, mg/g4.72 ± 0.204.69 ± 0.204.54 ± 0.275.10 ± 0.285.14 ± 0.22Heart weight/tibia length, mg/mm7.68 ± 0.497.91 ± 0.046.90 ± 0.477.46 ± 0.837.82 ± 0.47Lung weight/body weight, mg/g6.38 ± 0.606.69 ± 1.897.14 ± 0.377.10 ± 0.597.31 ± 0.54Lung weight/tibia length, mg/mm10.39 ± 1.1411.24 ± 2.7510.85 ± 0.6710.35 ± 0.8511.14 ± 1.32Liver weight/bodyweight, mg/g43.51 ± 3.6140.65 ± 5.9643.88 ± 3.8249.00 ± 6.1449.24 ± 5.04Liver weight/tibia length, mg/mm70.68 ± 4.8168.46 ± 7.3966.52 ± 4.1071.93 ± 12.5774.65 ± 4.74Spleen weight/bodyweight, mg/g2.91 ± 0.353.01 ± 0.904.30 ± 0.454.15 ± 0.824.37 ± 0.19Spleen weight/tibia length, mg/mm4.72 ± 0.555.05 ± 1.326.54 ± 0.766.09 ± 1.336.65 ± 0.25Kidney (R) weight/body weight, mg/g7.61 ± 0.578.17 ± 1.058.11 ± 0.247.97 ± 0.668.53 ± 0.82Kidney (R) weight/tibia length, mg/mm12.36 ± 0.6513.76 ± 1.2412.33 ± 0.6611.65 ± 1.3212.94 ± 0.79Kidney (L) weight/body weight, mg/g7.56 ± 0.558.30 ± 1.058.04 ± 0.357.87 ± 0.578.56 ± 0.54Kidney (L) weight/tibia length, mg/mm12.30 ± 0.9513.99 ± 1.2312.21 ± 0.5911.52 ± 1.3113.02 ± 1.10Lung water content, %84.43 ± 3.4581.08 ± 2.7879.04 ± 5.6085.47 ± 3.2384.12 ± 1.36Liver water content, %68.63 ± 0.6970.04 ± 0.6669.08 ± 3.0370.76 ± 1.8970.04 ± 1.24Spleen water content, %85.89 ± 2.4486.78 ± 1.5171.80 ± 11.3277.44 ± 14.5485.14 ± 2.99Age at day of infection, weeks10.46 ± 0.0510.40 ± 0.0010.48 ± 0.1010.48 ± 0.1010.52 ± 0.10 Day 14 Bodyweight, g29.02 ± 2.3829.06 ± 1.2727.10 ± 0.6527.35 ± 0.9028.50 ± 1.48Heart weight, mg141.20 ± 8.32137.00 ± 7.31139.17 ± 6.59131.17 ± 7.31133.00 ± 4.60Lung weight, mg178.80 ± 25.96174.80 ± 12.83239.17 ± 141.22200.17 ± 33.23182.00 ± 30.19Liver weight, mg1188.00 ± 167.831098.20 ± 83.921291.50 ± 233.091226.33 ± 119.331166.33 ± 76.07Spleen weight, mg85.00 ± 5.2484.60 ± 13.41104.67 ± 16.61132.00 ± 32.34105.17 ± 12.43Kidney (R) weight, mg214.00 ± 19.08203.80 ± 17.08214.17 ± 17.09209.67 ± 18.98209.83 ± 12.19Kidney (L) weight, mg219.60 ± 12.82208.80 ± 22.96216.67 ± 5.35203.33 ± 17.63211.33 ± 8.89Tibia length, mm17.20 ± 0.3117.06 ± 0.1817.12 ± 0.1917.13 ± 0.1517.23 ± 0.10Heart weight/body weight, mg/g4.90 ± 0.564.72 ± 0.345.14 ± 0.304.80 ± 0.224.67 ± 0.19Heart weight/tibia length, mg/mm8.22 ± 0.618.03 ± 0.388.13 ± 0.407.65 ± 0.407.72 ± 0.29Lung weight/body weight, mg/g6.16 ± 0.676.03 ± 0.538.76 ± 4.927.32 ± 1.256.41 ± 1.25Lung weight/tibia length, mg/mm10.40 ± 1.5910.25 ± 0.7713.97 ± 8.2611.68 ± 1.9310.56 ± 1.73Liver weight/bodyweight, mg/g41.28 ± 7.3637.76 ± 1.6147.68 ± 8.7044.79 ± 3.4141.03 ± 3.44Liver weight/tibia length, mg/mm69.09 ± 9.7664.41 ± 5.4675.43 ± 13.3871.55 ± 6.6567.66 ± 4.11Spleen weight/bodyweight, mg/g2.95 ± 0.412.92 ± 0.493.86 ± 0.594.81 ± 1.033.69 ± 0.41Spleen weight/tibia length, mg/mm4.95 ± 0.394.96 ± 0.796.11 ± 0.927.70 ± 1.846.10 ± 0.74Kidney (R) weight/body weight, mg/g7.40 ± 0.757.02 ± 0.657.90 ± 0.597.66 ± 0.617.37 ± 0.30Kidney (R) weight/tibia length, mg/mm12.45 ± 1.2411.95 ± 1.0012.52 ± 1.0312.23 ± 1.0512.18 ± 0.72Kidney (L) weight/body weight, mg/g7.61 ± 0.757.19 ± 0.788.00 ± 0.277.44 ± 0.727.42 ± 0.31Kidney (L) weight/tibia length, mg/mm12.78 ± 0.9312.24 ± 1.3512.66 ± 0.3911.87 ± 1.0012.26 ± 0.56Lung water content, %79.03 ± 4.4077.35 ± 2.9283.78 ± 4.1581.59 ± 4.1979.29 ± 4.72Liver water content, %67.90 ± 1.8267.83 ± 1.1366.66 ± 4.8267.48 ± 0.8867.36 ± 1.27Spleen water content, %82.64 ± 4.0383.05 ± 5.4780.01 ± 5.1275.90 ± 5.0978.01 ± 6.84Age at day of infection, weeks8.96 ± 0.469.34 ± 0.059.35 ± 0.058.67 ± 0.528.85 ± 0.45 Day 35 Bodyweight, g36.46 ± 1.6434.24 ± 5.4631.90 ± 2.8735.48 ± 4.5333.52 ± 3.58Heart weight, mg153.00 ± 2.92144.00 ± 12.79142.83 ± 11.05140.50 ± 9.68138.67 ± 8.82Lung weight, mg203.20 ± 8.38224.20 ± 22.69204.67 ± 44.59188.50 ± 10.47210.83 ± 22.23Liver weight, mg1368.60 ± 105.301284.60 ± 118.811176.33 ± 91.941271.75 ± 86.761307.33 ± 100.20Spleen weight, mg84.00 ± 3.8183.60 ± 9.9189.83 ± 8.8494.00 ± 9.2095.00 ± 7.10Kidney (R) weight, mg248.80 ± 9.26225.60 ± 25.97218.00 ± 21.19223.25 ± 19.62250.17 ± 59.52Kidney (L) weight, mg240.40 ± 19.59227.80 ± 14.79218.67 ± 22.04210.00 ± 15.03218.67 ± 15.15Tibia length, mm17.44 ± 0.1717.34 ± 0.0517.47 ± 0.2417.38 ± 0.1017.52 ± 0.21Heart weight/body weight, mg/g4.20 ± 0.154.25 ± 0.444.49 ± 0.313.99 ± 0.384.16 ± 0.33Heart weight/tibia length, mg/mm8.77 ± 0.108.30 ± 0.748.18 ± 0.678.08 ± 0.527.91 ± 0.42Lung weight/body weight, mg/g5.58 ± 0.236.72 ± 1.546.42 ± 1.245.37 ± 0.666.30 ± 0.42Lung weight/tibia length, mg/mm11.65 ± 0.5012.93 ± 1.3011.74 ± 2.6710.85 ± 0.6312.03 ± 1.19Liver weight/bodyweight, mg/g37.50 ± 1.3637.86 ± 2.9036.98 ± 2.5836.09 ± 2.8639.26 ± 3.65Liver weight/tibia length, mg/mm78.44 ± 5.3474.09 ± 6.8967.34 ± 5.1073.19 ± 4.9974.59 ± 4.85Spleen weight/bodyweight, mg/g2.31 ± 0.172.46 ± 0.142.82 ± 0.222.67 ± 0.272.85 ± 0.19Spleen weight/tibia length, mg/mm4.82 ± 0.244.82 ± 0.575.15 ± 0.535.41 ± 0.545.42 ± 0.35Kidney (R) weight/body weight, mg/g6.83 ± 0.196.65 ± 0.636.85 ± 0.526.32 ± 0.377.45 ± 1.48Kidney (R) weight/tibia length, mg/mm14.26 ± 0.4613.01 ± 1.5012.48 ± 1.2212.85 ± 1.1214.28 ± 3.40Kidney (L) weight/body weight, mg/g6.60 ± 0.496.75 ± 0.756.87 ± 0.515.95 ± 0.336.55 ± 0.37Kidney (L) weight/tibia length, mg/mm13.78 ± 1.0213.14 ± 0.8712.53 ± 1.3312.09 ± 0.8412.48 ± 0.80Lung water content, %80.11 ± 4.0382.72 ± 2.9977.90 ± 2.1972.55 ± 0.5781.36 ± 5.92Liver water content, %66.07 ± 0.7466.74 ± 1.4866.72 ± 0.9565.83 ± 1.2366.74 ± 1.53Spleen water content, %85.25 ± 1.7179.39 ± 4.6776.30 ± 5.2170.91 ± 5.4880.59 ± 9.11Age at day of infection, weeks10.42 ± 0.0410.56 ± 0.0810.60 ± 0.1010.62 ± 0.0410.50 ± 0.10 Day 56 Bodyweight, g33.80 ± 3.3334.98 ± 1.6832.27 ± 3.6932.25 ± 2.4134.03 ± 2.30Heart weight, mg145.25 ± 8.18153.20 ± 7.98141.67 ± 14.42156.50 ± 4.43150.17 ± 9.24Lung weight, mg223.75 ± 32.84203.00 ± 14.44229.83 ± 60.10207.75 ± 27.68235.00 ± 66.49Liver weight, mg1332.50 ± 159.261398.40 ± 113.881245.50 ± 170.291345.00 ± 114.001259.00 ± 85.39Spleen weight, mg79.25 ± 7.2397.20 ± 7.9589.17 ± 11.0392.00 ± 5.3590.50 ± 10.67Kidney (R) weight, mg229.00 ± 5.42246.40 ± 28.19227.33 ± 29.32254.75 ± 20.12232.17 ± 12.94Kidney (L) weight, mg233.00 ± 17.34242.00 ± 19.80236.17 ± 27.40245.50 ± 24.17235.33 ± 14.47Tibia length, mm17.43 ± 0.0517.52 ± 0.1917.35 ± 0.3117.50 ± 0.0017.45 ± 0.15Heart weight/body weight, mg/g4.32 ± 0.364.38 ± 0.264.40 ± 0.204.87 ± 0.274.42 ± 0.28Heart weight/tibia length, mg/mm8.34 ± 0.498.75 ± 0.498.16 ± 0.718.94 ± 0.258.61 ± 0.56Lung weight/body weight, mg/g6.68 ± 1.355.82 ± 0.527.10 ± 1.586.44 ± 0.626.84 ± 1.55Lung weight/tibia length, mg/mm12.84 ± 1.9111.59 ± 0.9013.23 ± 3.4011.87 ± 1.5813.47 ± 3.83Liver weight/bodyweight, mg/g39.46 ± 3.1140.02 ± 3.2738.60 ± 2.5341.78 ± 3.3937.04 ± 2.13Liver weight/tibia length, mg/mm76.47 ± 9.1879.84 ± 6.8271.71 ± 8.9076.86 ± 6.5172.15 ± 4.94Spleen weight/bodyweight, mg/g2.35 ± 0.182.79 ± 0.282.77 ± 0.232.86 ± 0.152.67 ± 0.33Spleen weight/tibia length, mg/mm4.55 ± 0.425.55 ± 0.505.14 ± 0.605.26 ± 0.315.18 ± 0.58Kidney (R) weight/body weight, mg/g6.82 ± 0.647.04 ± 0.717.05 ± 0.517.90 ± 0.206.85 ± 0.61Kidney (R) weight/tibia length, mg/mm13.14 ± 0.3514.07 ± 1.7013.08 ± 1.5014.56 ± 1.1513.30 ± 0.71Kidney (L) weight/body weight, mg/g6.91 ± 0.376.92 ± 0.527.33 ± 0.577.61 ± 0.386.94 ± 0.58Kidney (L) weight/tibia length, mg/mm13.37 ± 1.0213.82 ± 1.2213.60 ± 1.3914.03 ± 1.3813.48 ± 0.79Lung water content, %89.00 ± 1.0580.68 ± 2.4783.18 ± 5.3881.51 ± 2.8481.58 ± 4.26Liver water content, %67.39 ± 1.8566.72 ± 0.3567.92 ± 0.3168.34 ± 1.0266.17 ± 1.00Spleen water content, %NaN82.10 ± 5.1785.23 ± 2.9885.18 ± 4.2083.62 ± 3.33Age at day of infection, weeks10.06 ± 0.449.64 ± 0.059.65 ± 0.0510.15 ± 0.559.65 ± 0.05 Note: Group‐wise values for each allometric parameter, including mean ± standard deviation (SD). NaN, Not a Number (missing value). Allometric parameters of the characterization study. Note: Group‐wise values for each allometric parameter, including mean ± standard deviation (SD). NaN, Not a Number (missing value). Taken together, the dietary refinement using a purified amino acid formulation attenuates weight loss in CVB3‐infected mice while preserving cardiac inflammatory response. Multimodal imaging reveals progressive systolic dysfunction and regional strain abnormalities To compare the accuracy of different imaging modalities and comprehensively assess cardiac function following CVB3 infection, 1D short‐axis (SAX), 2D parasternal long‐axis (PLAX), and 4D echocardiography were performed across all 4 cohorts. Representative images and videos from day 56 vehicle‐ and virus (2×)‐treated animals are shown in Figure 4A–C and Supplemental Videos [Link], [Link], [Link], [Link], [Link], [Link]. A complete list of echocardiographic parameters is provided in Table S3. Comparison of imaging modalities for assessing left ventricular systolic function. (A, B) Representative echocardiographic images of SAX M‐mode (A) and PLAX B‐mode (B) from vehicle‐ and virus (2×)‐treated animals at day 56. Virus‐treated animals show reduced ventricular contraction. Dashed lines indicate endocardial tracings. (C) Surface renderings of reconstructions from 4D imaging. Panels show superimposed end‐diastolic and end‐systolic volumes from anterior and posterior views of vehicle‐ and virus (2×)‐treated animals at day 56. (D–F) Quantitation of LVEF using M‐mode (D), B‐mode (E), and 4D imaging (F). 4D imaging yields the most consistent measurements and shows reduced LVEF in virus‐treated animals at day 56. (G) Quantitation of cardiac output derived from 4D imaging, shows reduction in virus‐treated groups. Groups included vehicle and virus 0.5× (44 ± 10.5 PFU), 1× (88 ± 21 PFU), and 2× (176 ± 42 PFU) (n = 4–6 per group and timepoint). Data are presented as boxplots showing the median, interquartile range, and whiskers extending to the minimum and maximum values. Statistical significance is indicated as *p < 0.05, and **p < 0.01 based on comparisons against the vehicle group of each timepoint. Ao, aorta; d, day; LA, left atrium; LV; left ventricle; LVEF, left ventricular ejection fraction; PLAX, parasternal long‐axis; SAX, short‐axis. Quantification of LVEF across all modalities revealed a consistent trend of LVEF reduction in virus‐treated animals from day 35 onward, with the largest decrease observed in the virus (2×)‐treated groups, followed by the virus (1×)‐ and (0.5×)‐treated groups (Figure 4D–F). Given that LVEF measurements from SAX and PLAX rely on geometric assumptions, it is notable that 4D‐based LVEF quantification exhibited the lowest inter‐group coefficient of variation (CV) (SAX = 0.11, PLAX = 0.11, 4D = 0.09), supporting 4D imaging as the most accurate modality for LVEF assessment (Table S3). Significant reductions in 4D‐derived LVEF were observed in the virus (1×)‐ and (2×)‐treated groups at day 56 compared to vehicle. Similarly, cardiac output derived from 4D imaging was significantly reduced in all virus‐treated groups across days 35 and 56 post‐injection (Figure 4G). To detect subtler and regional myocardial dysfunction, global and segmental analyses of longitudinal, circumferential, and radial strain were performed (Figure 5A–D). Longitudinal strain was assessed from PLAX images (Figure 5A), while circumferential and radial strain were measured at basal, mid, and apical levels from SAX views (Figure 5B). GLS showed a trend toward reduction in the virus (2×)‐treated group at day 7 post‐injection. Additionally, GLS was significantly reduced in all virus‐treated groups from day 35 onward, with similar trends observed for global circumferential (GCS) and radial strain (Figure 5C). Consistent with LVEF measurements, virus (2×)‐treated animals showed the highest reductions in GLS and GCS at day 56, further supporting a dose‐dependent effect of CVB3 on cardiac dysfunction. Segmental strain analyses revealed a homogeneous reduction in longitudinal strain across all segments, whereas circumferential and radial strain impairments predominantly affected apical segments (Figure 5D). This regional pattern was evident by day 35 post‐injection (Figure S4A–C). Global and segmental analysis of longitudinal, circumferential, and radial strain. (A, B) Representative echocardiographic images from vehicle‐ and virus (2×)‐treated animals at day 56 showing peak systolic and diastolic strain. (A) Longitudinal strain in PLAX B‐mode images. (B) Circumferential and radial strain in SAX B‐mode images at basal, mid, and apical levels. Arrow length corresponds to the magnitude of strain. (C) Quantitation of global endocardial longitudinal, circumferential, and radial strain. Global longitudinal strain is severely reduced in all virus‐treated groups at days 35 and 56. (D) Bullseye maps showing segmental analysis of longitudinal, circumferential, and radial strain of vehicle‐ and virus (2×)‐treated animals at day 56. Apical segments show localized dysfunction in circumferential and radial strain in virus‐treated animals. Groups included vehicle and virus 0.5× (44 ± 10.5 PFU), 1× (88 ± 21 PFU), and 2× (176 ± 42 PFU) (n = 4–6 per group and timepoint). Data are presented as mean ± SD in bullseye maps or as boxplots showing the median, interquartile range, and whiskers extending to the minimum and maximum values. Statistical significance is indicated as **p < 0.01, and ***p < 0.001, based on comparisons against the vehicle group of each timepoint. d, day; PLAX, parasternal long‐axis; SAX, short‐axis; SD, standard deviation. Analysis of diastolic function via mitral valve Doppler showed no significant changes in diastolic function parameters at any timepoint (Figure S5A–D). Similarly, anterior and posterior left ventricular wall thicknesses were comparable across all groups and timepoints (Table S3). However, both end‐systolic and end‐diastolic left ventricular diameters (LVESD, LVEDD) showed a trend toward increase in all virus‐treated groups 56 days post‐injection, potentially indicating early ventricular dilation (Table S3). Taken together, these data demonstrate that CVB3 infection leads to progressive systolic dysfunction and regional myocardial strain abnormalities, with 4D echocardiography and strain analyses providing a highly sensitive and consistent assessment of cardiac impairment. DISCUSSION Refinement of preclinical models is essential to improve translational relevance while adhering to the principles of the 3Rs. 23 , 24 , 25 The present study highlights a refined model of CVB3‐induced myocarditis in BALB/cJ mice that integrates dietary and imaging innovations to enhance animal welfare and data quality. Pancreatic involvement is a well‐established feature of CVB3‐induced myocarditis in murine models, where the pancreas often exhibits greater viral tropism than the heart, leading to exocrine insufficiency and systemic illness. 45 , 46 , 47 , 48 , 49 , 55 While clinical pancreatitis is still found in infants following CVB3 infection, it is less frequently reported in adult viral myocarditis patients, suggesting differences in organ susceptibility and viral dissemination. 45 , 56 , 57 , 58 , 59 , 60 This discrepancy led to refinement of murine models to better reflect human disease. Notably, a pancreas‐attenuated engineered H3N‐375TS variant of CVB3, showed that pancreatic infection is not strictly required to elicit myocardial inflammation. 48 Additionally, pancreas‐specific deletion of coxsackievirus and adenovirus receptor, using pancreatic and duodenal homeobox 1‐Cre, attenuated pancreatic infection while maintaining cardiac inflammation. 61 However, infection of mice with the H3N‐375TS variant, did not induce cardiac dysfunction, suggesting that pancreatic inflammatory responses could be necessary to trigger functional cardiac impairment. These results underscore a critical trade‐off in model refinement. While attenuation of pancreatitis improves animal welfare, it may compromise the translational fidelity of the model, particularly for therapeutic efficacy studies targeting cardiac function. An alternative strategy is to preserve pancreatic infection while mitigating its systemic consequences. Historical data from fetal development studies have shown that hydrolyzed protein diets can compensate for CVB3‐induced pancreatic dysfunction in pregnant mice and restore normal fetal growth. 62 , 63 , 64 Consistent with these findings, our use of a hydrolyzed amino acid diet reduced body weight loss and stabilized blood glucose levels in infected animals. While previous studies reported a body weight loss of up to 30% compared to baseline, 20 , 21 , 65 , 66 our refined dietary approach limited this to approximately 5%. Importantly, this refinement did not attenuate cardiac inflammation, fibrosis, or the development of systolic dysfunction, thereby preserving the core pathological features of viral myocarditis. In addition to dietary refinements, we used advanced echocardiographic techniques to enhance the sensitivity and reproducibility of cardiac functional characterization of the viral CVB3 model. While conventional M‐ and B‐mode echocardiography remains valuable for measuring parameters like cardiac wall thickness and ventricular diameters, using these approaches for calculating LVEF relies on geometric assumptions that may not reflect the true ventricular anatomy. 34 , 35 , 36 , 37 , 38 , 39 In contrast, 4D echocardiography provides volumetric data based on real‐time 3D reconstructions. Accordingly, in our study, 4D‐derived LVEF exhibited the lowest inter‐group variability and was the only modality to detect significant systolic dysfunction across multiple virus‐treated groups at day 56 post‐injection. This increased precision not only improved data quality but also holds potential for reducing animal numbers in preclinical studies by lowering variability and increasing statistical power. Although LVEF is widely used to assess cardiac function, it often reflects late‐stage disease and lacks sensitivity for detecting early or regional myocardial dysfunction. 67 In this context, cardiac strain analysis has emerged as a powerful tool for identifying subtle changes. 20 , 68 , 69 , 70 Its clinical relevance is particularly evident in myocarditis, where patients frequently present with preserved LVEF but reduced GLS. 42 , 43 , 44 Notably, our model recapitulates this clinical pattern. GLS showed a trend toward reduction as early as 7 days post‐injection and reached statistical significance by day 35 onwards, whereas LVEF was only mildly reduced at day 56. These findings are consistent with previous reports in BALB/cJ mice, where early reductions in GLS were observed around day 10 post‐injection. 20 Interestingly, while the same study reported early GCS impairment, we observed significant GCS reduction only at later stages, suggesting potential differences in regional myocardial involvement or temporal disease progression. Despite its clinical relevance, strain analysis remains underutilized in preclinical models of viral myocarditis. Given its superior sensitivity and translatability to patient phenotypes, we propose that strain analysis should be considered a standard component in future preclinical studies. Considering the literature from the last 4 decades on the heart‐passaged CVB3 model using BALB/c mice, information on body weight changes during infection, general health status, mortality, cardiac function, and quantitative fibrosis is limited. Despite a significant reduction in body weight (~20%), no mortality has been reported during the first 1 to 2 weeks. 13 , 20 , 50 , 71 , 72 However, body weight can decrease by up to ~30% by week 3 after infection, with a survival rate of about 90% (personal communication Prof. Daniela Cihakova, observations until day 35). On day 10 post‐infection, analyzing only infected animals, there was a reduced ejection fraction (EF) in males compared with females. 73 The reduced EF was not different compared to day 0, and on day 35 end diastolic volume was also reduced. 74 Extended functional analysis showed consistent impaired function in BALB/cJ mice after 10 days of infection. 20 , 75 A recent study reported increased LVESD and LVEDD as early as 42 days post‐infection, accompanied by a reduction in LVEF. 31 Additionally, another study showed increased LVSED at 90 days post‐injection, without analyzing cardiac function. 76 Importantly, these studies used the same strain and age of animals, suggesting that differences in disease progression may be attributed to factors like viral dose. Changes in parameters like EF and end‐diastolic volume are not observed in other WT mouse lines such as C57BL/6 versus B6.129 mice 74 and are related to the susceptibility of the BALB/c mice to develop DCM as result of chronic inflammation. Finally, regarding cardiac fibrosis, the observations are variable and changes between 10% and 20% (10–35 days after infection) have been reported. 13 , 77 , 78 Highly variable scores between ~0.5 and 2 from days 14–42 after infection have also been reported. 31 However, it has also been reported that in BALB/c mice, fibrosis and necrosis are not obvious during acute myocarditis, but only appear in the chronic phase of disease around day 35 after infection. 50 Differences in the above reported observations could be a result of variations in protocols in addition to biological variability in mice as seen in patient populations. The following limitations should be considered. First, the study was not initially sufficiently statistically powered and initial sample sizes of treatment groups were limited. While consistent changes were observed across multiple endpoints, some did not reach statistical significance, especially in early timepoints following CVB3 infection. Increasing the sample size of each group would be required to confirm these differences. To support future study design, post hoc power calculations were performed (Figure S6A,B). Second, the observation period was limited to 56 days post‐injection. While this timeframe captured early and intermediate stages of viral myocarditis, including inflammation, mild fibrosis, and emerging systolic dysfunction, it did not reveal definitive signs of DCM. Fibrotic remodeling remained limited throughout the study period and did not show a clear progression over time, as pronounced fibrotic remodeling is typically associated with later stages of disease progression. Further, no significant increases in LVESD, LVEDD, or heart weight were observed (Tables 2 and S3). Finally, the study was conducted in BALB/cJ mice, which are known to exhibit a disease course distinct from C57BL/6 mice. While BALB/cJ mice are well suited to model chronic inflammation and progression toward DCM, C57BL/6 mice more commonly reflect acute disease phenotypes. 15 , 16 , 53 , 54 Therefore, the findings of the present study may require validation in additional strains. In conclusion, the refined CVB3 myocarditis model presented here contributes to the broader framework of responsible animal research. The inclusion of a detailed BSL2 workflow supports a culture of care that protects both animal welfare and the health of experimental personnel. Our dietary refinement and advanced imaging modalities not only enhanced animal welfare but also reduced data variability, enabling a reduction in required group sizes. Together, these refinements establish a comprehensive and reproducible standard for future studies, aligning with the principles of the 3Rs and promoting safety, ethical integrity, and translational relevance in preclinical research. AUTHOR CONTRIBUTIONS Jonas Stewen: Data curation; formal analysis; methodology; visualization; writing – original draft; writing – review and editing. Julia Riedesel: Data curation; formal analysis; methodology; writing – review and editing. Juliane Stein: Data curation; formal analysis; methodology; writing – review and editing. Brandon H. Greene: Data curation; formal analysis; methodology; visualization; writing – review and editing. Svenja Rohde: Data curation; formal analysis; methodology; project administration; supervision; writing – review and editing. Sonja Suess: Data curation; formal analysis; methodology; writing – review and editing. Bjoern Keiner: Project administration; writing – review and editing. Priya Panjwani: Project administration; writing – review and editing. Padmapriya Ponnuswamy: Conceptualization; project administration; supervision; writing – review and editing. Juan E. Camacho Londoño: Conceptualization; data curation; formal analysis; methodology; project administration; supervision; visualization; writing – original draft; writing – review and editing. FUNDING INFORMATION This research was funded by CSL Innovation GmbH. CONFLICT OF INTEREST STATEMENT Jonas Stewen, Julia Riedesel, Juliane Stein, Brandon Greene, Svenja Rohde, Sonja Suess, Bjoern Keiner, Priya Panjwani, Padmapriya Ponnuswamy and Juan E. Camacho Londoño are/were CSL Innovation GmbH (Germany) employees. Supporting information Supplementary Video 1: Short axis (SAX) echocardiographic view of a representative vehicle‐treated animal at day 56 post‐injection. Supplementary Video 2: Short axis (SAX) echocardiographic view of a representative virus (2×)‐treated animal at day 56 post‐injection. Supplementary Video 3: Parasternal long axis (PLAX) echocardiographic view of a representative vehicle‐treated animal at day 56 post‐injection. Supplementary Video 4: Parasternal long axis (PLAX) echocardiographic view of a representative virus (2×)‐treated animal at day 56 post‐injection. Supplementary Video 5: 4D echocardiographic volume reconstruction of a representative vehicle‐treated animal at day 56 post‐injection. Supplementary Video 6: 4D echocardiographic volume reconstruction of a representative virus (2×)‐treated animal at day 56 post‐injection. Figure S1.